Eribulin for advanced breast cancer: A drug evaluation

Journal of Breast Cancer

Volumn 16, Issue 1, 2013, Pages 12-15

  Shablak, Alaaeldin ^a  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast neoplasms; Eribulin; Microtubule inhibitor

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ERIBULIN; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; ECONOMIC ASPECT; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SARCOMA; SINGLE DRUG DOSE;

EID: 84876070394     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2013.16.1.12     Document Type: Review

References (26)

1. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-15.
2. Kingston DG. Taxol and its analogs. In: Cragg GM, Kingston DG, Newman DJ, editors. Anticancer Agents from Natural Products. 2nd ed. Boca Raton: CRC Press; 2005. p.123-35.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
4. Hirata Y, Ohya S. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-10.
5. Pettit GR, Herald CL, Boyd MR, Leet JE, Dufresne C, Doubek DL, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991;34:3339-40.
6. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-9.
7. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
8. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55:31-51.
9. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
10. Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5551-4.
11. Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5547-50.
12. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
13. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-9.
14. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
15. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23:1441-8.
16. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
17. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
18. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3.
19. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol 2012;7:574-8.
20. Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12:1045-52.
21. Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer 2012;118:2403-10.
22. Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2012;30:1203-7.
23. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 2011;29:352-9.
24. de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23:1241-9.
25. U.S. Food and Drug Administration on HALAVEN™ (eribulin mesylate) Injection. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf. Accessed January 4th, 2013.
26. Final appraisal determination on Eribulin for the treatment of locally advanced or metastatic breast cancer. National Institute for Health and Clinical Excellence. http://www.nice.org.uk/nicemedia/live/13238/57079/57079.pdf. Accessed January 4th, 2013.